We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00828412
Recruitment Status : Completed
First Posted : January 26, 2009
Results First Posted : December 9, 2013
Last Update Posted : January 30, 2017
Information provided by (Responsible Party):
Promius Pharma, LLC

Brief Summary:
This study compares the effectiveness of two topical creams for atopic dermatitis in pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice daily for 6 weeks or until clear.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Device: EpiCeram Skin Barrier Emulsion Drug: Desonide Cream 0.05% Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis
Study Start Date : March 2009
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
Drug Information available for: Desonide

Arm Intervention/treatment
Active Comparator: 1
EpiCeram Skin Barrier Emulsion
Device: EpiCeram Skin Barrier Emulsion
topical cream, twice daily, 6 weeks

Active Comparator: 2
Desonide Cream 0.05%
Drug: Desonide Cream 0.05%
topical cream, twice daily, 6 weeks

Primary Outcome Measures :
  1. Change From Baseline in Three Item Severity Score [ Time Frame: Baseline to 6 weeks ]
    The average of the sum of scores for erythema, edema/papulation, and excoriation for two target lesions. Scoring on a scale of 0 to 3 (none to severe). Maximum score is 9.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Months to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • at least 3 months of age and less than 13 years of age
  • atopic dermatitis of moderate severity

Exclusion Criteria:

  • pregnant or lactating
  • treatment of atopic dermatitis with topical product in the 14 days prior to Baseline
  • treatment of atopic dermatitis with systemic product in the 30 days prior to Baseline
  • serious or uncontrolled medical condition
  • active infection
  • significant use of inhaled, intranasal, or intraocular corticosteroid

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00828412

Layout table for location information
United States, Colorado
National Jewish Health
Denver, Colorado, United States, 80206
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, North Carolina
Wake Forest University Health Sciences
Winston Salem, North Carolina, United States, 27157
United States, Ohio
Dermatology Research Associates
Cincinnati, Ohio, United States, 45230
United States, Texas
University of Texas
Houston, Texas, United States, 77030
Sponsors and Collaborators
Promius Pharma, LLC
Layout table for investigator information
Study Director: Joanne Fraser, PhD Promius Pharma, LLC
Layout table for additonal information
Responsible Party: Promius Pharma, LLC
ClinicalTrials.gov Identifier: NCT00828412    
Other Study ID Numbers: EPC0801
First Posted: January 26, 2009    Key Record Dates
Results First Posted: December 9, 2013
Last Update Posted: January 30, 2017
Last Verified: December 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents